ANDA 88475, held by Abraxis Pharm. Glycopyrrolate.
As of Nov 15, 2026, ANDA 88475 (Glycopyrrolate), held by Abraxis Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Glycopyrrolate0.2MG/ML ยท injectable;injection | Glycopyrrolate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
